Previous 10 | Next 10 |
ATLAS™ identifies naturally occurring neoantigen-specific inhibitory T cell responses that are augmented after vaccination Inhibitory T cell responses exacerbate tumor growth CAMBRIDGE, Mass., Nov. 09, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GN...
Proportions of inhibitory neoantigens found in cancer patients with the ATLAS™ biology-driven platform may also predict patient responses to immunotherapy Confirm positive GEN-009 clinical immunogenicity results CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE N...
Genocea Biosciences Inc (GNCA) Q3 2019 Results Earnings Conference Call October 24, 2019 08:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Chip Clark - President and CEO Diantha Duvall - CFO Tom Davis - Chief Medical Officer Jessica Flechtner ...
Cellect Biotechnology (NASDAQ: APOP ) +43% after reverse split & ADS ratio change. More news on: Cellect Biotechnology Ltd., PDS Biotechnology Corporation, Genocea Biosciences, Inc., Stocks on the move, Read more ...
Genocea Biosciences ( GNCA ) Q3 results : Revenues: $0; R&D Expense: $6.8M (+6.2%); SG&A: $2.7M (-34.1%); Operating loss: ($9.6M) (+8.6%); Net loss: ($7.5M) (+3.8%); loss/share: ($0.28) (+61.1%); Quick Assets: $46.6M (+76.5%). More news on: Genocea Biosciences, Inc., Healthcare st...
Genocea Biosciences (NASDAQ: GNCA ): Q3 GAAP EPS of -$0.28 beats by $0.18 . More news on: Genocea Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2019 financial results and corporate update conference call and live audio webcast...
The following slide deck was published by Genocea Biosciences, Inc. in conjunction with this Read more ...
Additional p ositive GEN-009 c linical i mmunogenicity d ata d riven by ATLAS™ to be p resented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Genocea Bio...
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and chief executive officer, will present at two leading healthcare confer...
News, Short Squeeze, Breakout and More Instantly...
Genocea Biosciences Inc. Company Name:
GNCA Stock Symbol:
NASDAQ Market:
Genocea Biosciences Inc. Website: